1. “Competitor Intelligence “
Market overview
Assim Abdel Halim
Professional Medical Representative
DBU – Merck Saudi Arabia

3. 1. Who We Are . . !
*DORZOLAMIDE
2%+TIMOLOL 5%.
*80 SR .
*COMBINATION
THERAPY.
*CARBONIC
ANHYDRAZE
INHIBITOR + B-
BLOKER.
*MARKET LEADER.
*THE MOST
EFFECTIVE &
TRUSTED ONE.
*UNIQUE DEVICE.
*COSOPT PF :
PRESERVATIVE
FREE
COMBINATION
COSOPT
COSOPT PF*
 TRUSOPT
 TIMPOTOL

4. 2. Our competitors :
 ALLERGAN: ( Lumigan-Ganfort-Alphagan-
Combigan ).
 ALCON: ( Betoxolol- Travatan-Duotrov-Azopt-
Azarga ).
 PFIZER: ( Xalatan-Xalacom ).
3. Generic :
 Jamjoom  xola-xolamol .

5. ALLERGAN BRANDS

6. ALCON BRANDS
*Travantan(66
SR)
*Travoprost 0.004%
*Monotharpy
*Duotrov (71.5 SR)
*Travan + Timolol 5%
*Combination.
*Azopt ( 44 SR )
* Brinzolamide 10%
*Monotherapy
*Azarga ( 64.80 SR)
* Azopt + Timolol 5%
*Combination therapy
*Betoptic (36.8 SR)
* Betoxolol 5%
*Monotherapy

7. PFIZER BRANDS
*Xalatan (76 SR )
*Latanoprost
0.005%
*Monotherapy
*Xalacom ( 89.5 SR )
*Xalatan + 5%
Timolol
*No Added value
than Xalatan .

8. Generic product
( Jamjoom )
*Xola (34
SR)
*Dorzolami
de
*Xolamol (51
SR )
*Dorzolamide
+ Timolol

9. 4. Who will be our main
competitors ?
a) Combination dosage forms .
b) Generic forms .
• Our key actions :
* Clinical credibility – Rapport building – Adapting
our message – Optimum resources allocation.
*Anti-generic campaign .

10. *BRAND vs GENERIC
Figure 1 :
INNOVATION.
VALUE FOR
MONEY.

11. So, we can lead forever.

 T H A N K S 